Prevalence, risk factors and clinical characteristics in patients with genotype 6 chronic hepatitis C: a single institute experience
- Authors
- Shin S.K.; Park S.Y.; Jung Y.K.; Kim E.J.; Lee H.N.; Lee J.J.; Kwon O.S.; Choi D.J.; Kim Y.S.; Kim J.H.
- Issue Date
- 2015
- Publisher
- 대한소화기학회
- Citation
- 대한소화기학회지, v.65, no.2, pp 105 - 111
- Pages
- 7
- Indexed
- SCOPUS
KCI
- Journal Title
- 대한소화기학회지
- Volume
- 65
- Number
- 2
- Start Page
- 105
- End Page
- 111
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/8392
- DOI
- 10.4166/kjg.2015.65.2.105
- ISSN
- 1598-9992
2233-6869
- Abstract
- BACKGROUND/AIMS: Hepatitis C genotypes 1 and 2 are widely distributed globally. In contrast, genotype 6 is found mainly in Southeast Asia, while genotype 6 is rare in Korea. This study aims to investigate the prevalence, risk factors and clinical characteristics of patients with genotype 6 chronic hepatitis C.METHODS: We retrospectively identified 133 HCV-infected patients who underwent HCV genotype analysis between January 2012 and December 2012, and analyzed the prevalence, risk factors and clinical characteristics of patients diagnosed with genotype 6 chronic hepatitis C.RESULTS: Among 133 patients, 53 patients (39.8%) were infected with genotype 1, 62 patients (46.6%) with genotype 2, 2 patients (1.5%) with genotype 3, 14 patients (10.5%) with genotype 6, and 2 patients (1.5%) with mixed genotypes (genotype 1 and 6). The risk factors associated with genotype 6 were acupuncture (n=4, 28.6%), intravenous drug use (n=3, 21.4%), tattoo (n=2, 14.3%), and transfusion (n=2, 14.3%). Of the 14 patients with genotype 6, 6 patients were treated with pegylated interferon and ribavirin. Five patients had reached the end of treatment. All patients reaching end of treatment for genotype 6 showed early virological response and sustained virological response.CONCLUSIONS: The prevalence of genotype 6 is 10.5% and mixed infections of genotype 1 and 6 are 1.5% in patients with chronic hepatitis C. A major potential risk factor is intravenous drug use and the treatment response rate to pegylated interferon plus ribavirin is high in patients with genotype 6 chronic hepatitis C. Large scale multicenter studies are needed.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/8392)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.